$INM
InMed Pharmaceuticals Inc. Stock $inm

$inm Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000121390024082843 Filed on September 30, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$1.265M	$1.283M	$4.598M
YoY Change	40.23%	-44.46%	11.18%
Cost Of Revenue	$771.2K	$817.0K	$3.497M
YoY Change	-2.09%	10.41%	44.28%
Gross Profit	$493.4K	$466.1K	$1.101M
YoY Change	2222.82%	-70.31%	-21.53%
Gross Profit Margin	39.02%	36.32%	23.94%
Selling, General & Admin	$1.422M	$1.214M	$5.251M
YoY Change	9.38%	-13.91%	-10.24%
% of Gross Profit	288.18%	260.46%	476.94%
Research & Development	$771.2K	$1.206M	$3.765M
YoY Change	-40.32%	94.58%	0.88%
% of Gross Profit	156.3%	258.84%	341.99%
Depreciation & Amortization	$54.58K	$54.77K	$219.6K
YoY Change	-0.46%	9.54%	8.58%
% of Gross Profit	11.06%	11.75%	19.95%
Operating Expenses	$2.228M	$2.475M	$9.297M
YoY Change	-17.29%	18.42%	-4.95%
Operating Profit	-$1.735M	-$2.009M	-$8.196M
YoY Change	-31.61%	286.35%	3.13%
Interest Expense	$76.40K	$78.44K	$466.0K
YoY Change	-15.11%	-56.42%	5.9%
% of Operating Profit
Other Income/Expense, Net			$527.9K
YoY Change			22.44%
Pretax Income	-$1.678M	-$1.931M	-$7.668M
YoY Change	-33.86%	467.81%	-3.35%
Income Tax		$7.100K	$7.100K
% Of Pretax Income
Net Earnings	-$1.678M	-$1.938M	-$7.700M
YoY Change	-32.89%	469.9%	-3.12%
Net Earnings / Revenue	-132.68%	-151.02%	-167.47%
Basic Earnings Per Share	-$2.71		-$1.01
Diluted Earnings Per Share	-$2.71	-$0.20	-$1.01
COMMON SHARES
Basic Shares Outstanding	13.34M shares	8.358M shares	7.621M shares
Diluted Shares Outstanding	620.1K shares		7.621M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.626M	$6.615M	$6.615M
YoY Change	-17.02%	-26.18%	-26.18%
Cash & Equivalents	$5.583M	$6.572M	$6.572M
Short-Term Investments	$43.20K	$43.06K	$43.06K
Other Short-Term Assets	$148.9K	$477.8K	$477.8K
YoY Change	-32.33%	-4.45%	-4.45%
Inventory	$1.220M	$1.244M	$1.244M
Prepaid Expenses
Receivables	$284.7K	$352.8K	$352.8K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.280M	$8.690M	$8.690M
YoY Change	-12.24%	-23.32%	-23.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.343M	$1.250M	$1.250M
YoY Change	118.36%	72.79%	73.61%
Goodwill
YoY Change
Intangibles	$1.742M	$1.783M
YoY Change		-8.38%
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$100.0K
YoY Change	-1.76%	-4.68%	0.0%
Total Long-Term Assets	$3.185M	$3.133M	$3.133M
YoY Change	21.47%	12.92%	12.7%
TOTAL ASSETS
Total Short-Term Assets	$7.280M	$8.690M	$8.690M
Total Long-Term Assets	$3.185M	$3.133M	$3.133M
Total Assets	$10.47M	$11.82M	$11.82M
YoY Change	-4.14%	-16.19%	-16.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.000K	$41.00K	$626.2K
YoY Change	-99.47%	-92.41%	15.96%
Accrued Expenses	$85.52K	$256.5K	$1.305M
YoY Change	-91.09%	-82.19%	-9.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.436M	$1.972M	$1.972M
YoY Change	7.22%	-1.44%	-1.41%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$633.8K	$644.9K	$644.9K
YoY Change		3124.35%	3124.35%
Total Long-Term Liabilities	$633.8K	$644.9K	$644.9K
YoY Change		3124.35%	3124.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.436M	$1.972M	$1.972M
Total Long-Term Liabilities	$633.8K	$644.9K	$644.9K
Total Liabilities	$2.070M	$2.617M	$2.617M
YoY Change	54.54%	29.76%	29.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.8M	-$109.1M
YoY Change	6.64%	7.59%
Common Stock	$119.0M	$118.2M
YoY Change	4.97%	52.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.395M	$9.206M	$9.206M
YoY Change
Total Liabilities & Shareholders Equity	$10.47M	$11.82M	$11.82M
YoY Change	-4.14%	-16.19%	-16.21%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$1.678M	-$1.938M	-$7.700M
YoY Change	-32.89%	469.9%	-3.12%
Depreciation, Depletion And Amortization	$54.58K	$54.77K	$219.6K
YoY Change	-0.46%	9.54%	8.58%
Cash From Operating Activities	-$1.827M	-$1.029M	-$6.986M
YoY Change	-15.98%	58.33%	-4.08%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$9.293K
YoY Change		-100.0%	-94.19%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities		$0.00	-$9.293K
YoY Change		-100.0%	-98.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$838.2K	180.0	$4.654M
YoY Change			-56.42%
NET CHANGE
Cash From Operating Activities	-$1.827M	-1.029M	-$6.986M
Cash From Investing Activities		0.000	-$9.293K
Cash From Financing Activities	$838.2K	180.0	$4.654M
Net Change In Cash	-$988.6K	-1.029M	-$2.341M
YoY Change	-54.53%	51.32%	-185.57%
FREE CASH FLOW
Cash From Operating Activities	-$1.827M	-$1.029M	-$6.986M
Capital Expenditures		$0.00	$9.293K
Free Cash Flow		-$1.029M	-$6.995M
YoY Change		27.06%	-6.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-39685
CY2024	dei	Entity Registrant Name EntityRegistrantName	INMED PHARMACEUTICALS INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1428279
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	1445, 885 West Georgia St
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Vancouver
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	B.C
CY2024	dei	Entity Address Country EntityAddressCountry	CA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V6C 3E8
CY2024	dei	City Area Code CityAreaCode	(604)
CY2024	dei	Local Phone Number LocalPhoneNumber	669-7207
CY2024	dei	Security12b Title Security12bTitle	Common Stock, no par value
CY2024	dei	Trading Symbol TradingSymbol	INM
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	2351381	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13340245	shares
CY2024	dei	Auditor Firm AuditorFirmId	688
CY2024	dei	Auditor Name AuditorName	Marcum LLP
CY2024	dei	Auditor Location AuditorLocation	New York, NY
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6571610	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8912517	usd
CY2024Q2	us-gaap	Short Term Investments ShortTermInvestments	43064	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	44422	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	66775	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	352838	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	260399	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1244324	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1616356	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	477749	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	498033	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	8689585	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	11331727	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1249999	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723426	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1783198	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1946279	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	100000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104908	usd
CY2024Q2	us-gaap	Assets Assets	11822782	usd
CY2023Q2	us-gaap	Assets Assets	14106340	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1654011	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1608735	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	317797	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	375713	usd
CY2023Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	16171	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1971808	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2000619	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	644865	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15994	usd
CY2024Q2	us-gaap	Liabilities Liabilities	2616673	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2016613	usd
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8918956	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8918956	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3328191	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3328191	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	82784400	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	77620252	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35368899	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35741115	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109075759	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101400209	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	9206109	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11822782	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14106340	usd
CY2024	us-gaap	Revenues Revenues	4597730	usd
CY2023	us-gaap	Revenues Revenues	4135561	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	3496817	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	2732525	usd
CY2024	us-gaap	Gross Profit GrossProfit	1100913	usd
CY2023	us-gaap	Gross Profit GrossProfit	1403036	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3765028	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3732056	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5250715	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5847518	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	219600	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	202249	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-61921	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-48175	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	9297264	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9829998	usd
CY2024	us-gaap	Investment Income Interest InvestmentIncomeInterest	527901	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	492440	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7668450	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7934522	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7100	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13100	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7675550	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7947622	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.25
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7621075	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2448458	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2024	inm	Stock Issued During Period Value Issued For Private Placement StockIssuedDuringPeriodValueIssuedForPrivatePlacement	5216194	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	562151	usd
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	175	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7675550	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	137714	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	9206109	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9078541	usd
CY2023	inm	Stock Issued During Period Value Issued For Private Placement StockIssuedDuringPeriodValueIssuedForPrivatePlacement	11999790	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2011266	usd
CY2023	inm	Agents Investment Options AgentsInvestmentOptions	691483	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	646	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7947622	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	278155	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7675550	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7947622	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	219600	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	202249	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	137714	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	278155	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	384918	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	393748	usd
CY2024	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	1250	usd
CY2023	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	803	usd
CY2024	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	12262	usd
CY2023	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	1183	usd
CY2024	us-gaap	Inventory Write Down InventoryWriteDown	305812	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	308937	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	46775	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-66220	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-565561	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-20284	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-299192	usd
CY2024	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4908	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-5507	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	92439	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	219147	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	45282	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-806530	usd
CY2024	inm	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	16171	usd
CY2023	inm	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-16171	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-397422	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-426575	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6985832	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7283199	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	500000	usd
CY2023	us-gaap	Payments For Other Deposits PaymentsForOtherDeposits	1790	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9293	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	160014	usd
CY2024	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	42082	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	42268	usd
CY2024	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	42082	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	42268	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9293	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-661804	usd
CY2024	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	175	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	646	usd
CY2024	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4654043	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10680008	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4654218	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10680654	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2340907	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2735651	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8912517	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6176866	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6571610	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8912517	usd
CY2024	us-gaap	Income Taxes Paid IncomeTaxesPaid	7100	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	13100	usd
CY2024	us-gaap	Stock Issued1 StockIssued1	325699	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	691484	usd
CY2024	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3508749	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	968376	usd
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CORPORATE INFORMATION AND CONTINUING OPERATIONS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the <i>Business Corporations Act</i> of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s office and principal place of business is located at Suite 1445– 885 West Georgia Street, Vancouver, B.C., Canada, V6C 1B4.</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 1.2pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Through June 30, 2024, the Company has funded its operations primarily with proceeds from the sale of Common Shares. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of approximately $7.7 million and $7.9 million for the years ended June 30, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of approximately $109.1 million as of June 30, 2024. The Company expects to continue to generate operating losses for the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of the issuance date of these consolidated annual financial statements, the Company expects its cash, cash equivalents and short-term investments of $6.6 million as of June 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements to the end of the fourth quarter of calendar 2024, depending on the level and timing of realizing BayMedica revenues from the sale of bulk rare cannabinoids in the health & wellness sector as well as the level and timing of the Company operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In connection with the Company’s assessment of going concern considerations in accordance with Subtopic 205-40, management has determined that the Company’s liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern, which is considered to be for a period of one year from the issuance of these financial statements. These consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts of classification of liabilities that might result from the outcome of this uncertainty. Such adjustments could be material.</p>
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7700000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7900000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109100000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	6600000	usd
CY2024	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Certain prior year amounts in the consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year’s presentation. These reclassifications did not affect the prior period’s total assets, total liabilities, stockholders’ deficit, net loss or net cash used in operating activities. During the three months and nine months ended March 31, 2024, we adopted a change in presentation on our consolidated statements of operations in order to include foreign exchange loss in operating expenses. The Company has adopted ASU 2023-07 - Improvements to Reportable Segment Disclosures which has required prior period to reflect the change in presentation. Refer to discussion on Recent Accounting Pronouncements below.</p>
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The preparation of financial statements in compliance with US GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these consolidated financial statements are the application of the going concern assumptions, determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, warrant valuations, and the assumptions used in the determination of research & development accruals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Actual results could differ from those estimates.</p>
CY2024Q2	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	1939482	usd
CY2023Q2	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	1478487	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	66775	usd
CY2024	us-gaap	Proceeds Accounts Receivable Previously Written Off Recovery ProceedsAccountsReceivablePreviouslyWrittenOffRecovery	66775	usd
CY2023	us-gaap	Proceeds Accounts Receivable Previously Written Off Recovery ProceedsAccountsReceivablePreviouslyWrittenOffRecovery	0	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) or Canadian Deposit Insurance Corporation (CDIC) insurable limits. The Company has not experienced any losses related to these balances. The uninsured cash balance as of June 30, 2024, was $2.4 million. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company’s customers are primarily concentrated in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of June 30, 2024, we had five customers with an accounts receivable balance representing 32%, 20%, 15%,15% and 14% of total accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For the year ended June 30, 2024, the Company had five customers that accounted for 34%, 18%, 14%, 12% and 10% of revenue. For the year ended June 30, 2023, the Company had four customers that accounted for 22%, 17%, 16% and 11% of revenue.</p>
CY2024Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	2400000	usd
CY2024	inm	Inventory Write Down Due To Net Realizable Value InventoryWriteDownDueToNetRealizableValue	103136	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	308937	usd
CY2024	inm	Inventory Writedown Due To Obsolete InventoryWritedownDueToObsolete	208737	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	694017	shares
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10866517	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3619171	shares
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	372695	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	208737	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	30817	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	514113	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	840812	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	893506	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1244324	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1616356	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9614	usd
CY2023Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	308937	usd
CY2024Q2	us-gaap	Weighted Average Cost Inventory Amount WeightedAverageCostInventoryAmount	103434	usd
CY2023Q2	us-gaap	Weighted Average Cost Inventory Amount WeightedAverageCostInventoryAmount	93820	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2605310	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1648747	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1355311	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	925321	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1249999	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723426	usd
CY2024	us-gaap	Depreciation Depreciation	47742	usd
CY2023	us-gaap	Depreciation Depreciation	39613	usd
CY2024Q2	inm	Finite Lived Intellectual Property FiniteLivedIntellectualProperty	1736420	usd
CY2023Q2	inm	Finite Lived Intellectual Property FiniteLivedIntellectualProperty	1736420	usd
CY2024Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2023Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1144222	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	981141	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1783198	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1946279	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P18Y
CY2024Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
CY2024	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P11Y
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	171858	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	159228	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	162746	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	162746	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	162746	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	162746	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	162746	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	969468	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1783198	usd
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	626190	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	544179	usd
CY2024Q2	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	242066	usd
CY2023Q2	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	164587	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	41004	usd
CY2024Q2	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	488278	usd
CY2023Q2	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	542305	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	256473	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	357664	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1654011	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1608735	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.83
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y6M
CY2023Q4	inm	Preferred Investment Of Fair Value Options PreferredInvestmentOfFairValueOptions	1251449	usd
CY2024Q2	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	1491138	usd
CY2024	inm	Fair Value Of Issuance Date FairValueOfIssuanceDate	1225230	usd
CY2024	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	1796552	shares
CY2024	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3500000	usd
CY2023Q4	us-gaap	Payments For Fees PaymentsForFees	560000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	408511	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.0375
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y6M
CY2022Q3	us-gaap	Other Investments OtherInvestments	77242	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1052101	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.44
CY2022Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P7Y
CY2022Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	150000	shares
CY2022Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5999844	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	38713	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	831292	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	184539	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20	pure
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	700000	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	51633	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	57800	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1.32
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.37
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	55603	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	128.59
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	61720	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.85
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	14681	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	267.13
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	102642	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.28
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	580400	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.37
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	8569	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	164.34
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	674473	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.89
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	51067	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	57.44
CY2023	inm	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedNumber	51575	shares
CY2023	inm	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageGrantDateFairValue	5.38
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	112920	shares
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	14.9
CY2024	inm	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedNumber	561553	shares
CY2024	inm	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageGrantDateFairValue	0.4
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	137714	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	278154	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y4M17D
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	364887	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	366753	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	313231	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1044871	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	82209	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	962662	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	317797	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	644865	usd
CY2019Q3	us-gaap	Area Of Land AreaOfLand	2243	sqm
CY2019Q3	us-gaap	Payments For Rent PaymentsForRent	12296	usd
CY2019Q3	inm	Estimated Agreement Term EstimatedAgreementTerm	two-year
CY2024	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	1295759	usd
CY2024	us-gaap	Lessee Operating Lease Option To Terminate LesseeOperatingLeaseOptionToTerminate	three-year
CY2024	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.0615	pure
CY2024Q2	inm	Corresponding Operating Lease Liability CorrespondingOperatingLeaseLiability	953935	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27	pure
CY2024	inm	Effective Income Tax Rate Reconciliation Income Tax Expenserecovery At The Statutory Rate EffectiveIncomeTaxRateReconciliationIncomeTaxExpenserecoveryAtTheStatutoryRate	1966981	usd
CY2023	inm	Effective Income Tax Rate Reconciliation Income Tax Expenserecovery At The Statutory Rate EffectiveIncomeTaxRateReconciliationIncomeTaxExpenserecoveryAtTheStatutoryRate	2073116	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1625998	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2532867	usd
CY2024	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-21942	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	9638	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	39252	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	76605	usd
CY2024	inm	Income Tax Reconciliation True Up To The Return IncomeTaxReconciliationTrueUpToTheReturn	303595	usd
CY2024	inm	Income Tax Reconciliation State Rate Change IncomeTaxReconciliationStateRateChange	2949	usd
CY2024	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	618907	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	417194	usd
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-123415	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-553877	usd
CY2024	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-135927	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	396211	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7100	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13100	usd
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	72724671	usd
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	67875659	usd
CY2024Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	21501476	usd
CY2023Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	19490270	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	861867	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1265542	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	12831	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	11638	usd
CY2024Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	146193	usd
CY2023Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	131714	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	241270	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	241270	usd
CY2024Q2	inm	Deferred Income Tax Lease Liability DeferredIncomeTaxLeaseLiability	164288	usd
CY2023Q2	inm	Deferred Income Tax Lease Liability DeferredIncomeTaxLeaseLiability	98827	usd
CY2024Q2	inm	Deferred Tax Assetscurrent DeferredTaxAssetscurrent	22927925	usd
CY2023Q2	inm	Deferred Tax Assetscurrent DeferredTaxAssetscurrent	21239261	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	116231	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	119889	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-157701	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-91377	usd
CY2024Q2	inm	Deferred Tax Assets Noncurrent DeferredTaxAssetsNoncurrent	-273932	usd
CY2023Q2	inm	Deferred Tax Assets Noncurrent DeferredTaxAssetsNoncurrent	-211266	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22653993	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21027995	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22653993	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21027995	usd
CY2024	us-gaap	Revenues Revenues	4597730	usd
CY2023	us-gaap	Revenues Revenues	4135561	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	3496817	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	2732525	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	9297264	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9829998	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	527901	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	492440	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7668450	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7934522	usd
CY2024Q2	us-gaap	Cash Cash	6571610	usd
CY2023Q2	us-gaap	Cash Cash	8912517	usd
CY2024	us-gaap	Cost Direct Material CostDirectMaterial	1500000	usd
CY2024	us-gaap	Equipment Expense EquipmentExpense	700000	usd
CY2024Q2	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	43064	usd
CY2023Q2	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	44422	usd
CY2021Q1	inm	Warrants To Purchase WarrantsToPurchase	700	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	700	shares
CY2023Q2	inm	Agreement Amount AgreementAmount	300000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent		usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.25
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2448458	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7621075	shares
CY2024	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2024	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2024	us-gaap	Payments For Other Deposits PaymentsForOtherDeposits		usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2023	inm	Inventory Writedown Due To Obsolete InventoryWritedownDueToObsolete		usd
CY2024Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet		usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent		usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive		usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023	inm	Income Tax Reconciliation True Up To The Return IncomeTaxReconciliationTrueUpToTheReturn		usd
CY2023	inm	Income Tax Reconciliation State Rate Change IncomeTaxReconciliationStateRateChange		usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2024Q2	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	72	usd
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001728328

Files In Submission

Name	View Source	Status
0001213900-24-082843-index-headers.html	Edgar Link	pending
0001213900-24-082843-index.html	Edgar Link	pending
0001213900-24-082843.txt	Edgar Link	pending
0001213900-24-082843-xbrl.zip	Edgar Link	pending
ea0214241-10k_inmed.htm	Edgar Link	pending
ea021424101ex10-19_inmed.htm	Edgar Link	pending
ea021424101ex10-20_inmed.htm	Edgar Link	pending
ea021424101ex21-1_inmed.htm	Edgar Link	pending
ea021424101ex23-1_inmed.htm	Edgar Link	pending
ea0214241-10k_inmed_htm.xml	Edgar Link	completed
ea021424101ex31-1_inmed.htm	Edgar Link	pending
ea021424101ex31-2_inmed.htm	Edgar Link	pending
ea021424101ex32-1_inmed.htm	Edgar Link	pending
ea021424101ex32-2_inmed.htm	Edgar Link	pending
ea021424101ex4-13_inmed.htm	Edgar Link	pending
ea021424101ex97-1_inmed.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
inm-20240630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
inm-20240630_cal.xml	Edgar Link	unprocessable
inm-20240630_def.xml	Edgar Link	unprocessable
inm-20240630_lab.xml	Edgar Link	unprocessable
inm-20240630_pre.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INM
InMed Pharmaceuticals Inc. Stock $inm

2024 Q3 Form 10-K Financial Statement

#000121390024082843 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM InMed Pharmaceuticals Inc. Stock $inm

2024 Q3 Form 10-K Financial Statement

#000121390024082843 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM
InMed Pharmaceuticals Inc. Stock $inm